205 related articles for article (PubMed ID: 36594088)
1. Validation of ESM1 Related to Ovarian Cancer and the Biological Function and Prognostic Significance.
Li YK; Zeng T; Guan Y; Liu J; Liao NC; Wang MJ; Chen KX; Luo XY; Chen CY; Quan FF; Wang J; Zhang QF; Zou J
Int J Biol Sci; 2023; 19(1):258-280. PubMed ID: 36594088
[No Abstract] [Full Text] [Related]
2. ANGPTL4 accelerates ovarian serous cystadenocarcinoma carcinogenesis and angiogenesis in the tumor microenvironment by activating the JAK2/STAT3 pathway and interacting with ESM1.
Li YK; Gao AB; Zeng T; Liu D; Zhang QF; Ran XM; Tang ZZ; Li Y; Liu J; Zhang T; Shi GQ; Zhou WC; Zou WD; Peng J; Zhang J; Li H; Zou J
J Transl Med; 2024 Jan; 22(1):46. PubMed ID: 38212795
[TBL] [Abstract][Full Text] [Related]
3. Identification and validation of IRF6 related to ovarian cancer and biological function and prognostic value.
Hong S; Fu N; Sang S; Ma X; Sun F; Zhang X
J Ovarian Res; 2024 Mar; 17(1):64. PubMed ID: 38493179
[TBL] [Abstract][Full Text] [Related]
4. Pan-cancer analysis identifies ESM1 as a novel oncogene for esophageal cancer.
Cui Y; Guo W; Li Y; Shi J; Ma S; Guan F
Esophagus; 2021 Apr; 18(2):326-338. PubMed ID: 33175267
[TBL] [Abstract][Full Text] [Related]
5. ESM1 Is a Promising Therapeutic Target and Prognostic Indicator for Esophageal Carcinogenesis/Esophageal Squamous Cell Carcinoma.
Li J; Yang D; Zhang C; Wei S; Zhao R; Dai S; Shan B
Biomed Res Int; 2022; 2022():5328192. PubMed ID: 35937390
[TBL] [Abstract][Full Text] [Related]
6. PRR11 Overexpression Facilitates Ovarian Carcinoma Cell Proliferation, Migration, and Invasion Through Activation of the PI3K/AKT/β-Catenin Pathway.
Zhu J; Hu H; Wang J; Yang Y; Yi P
Cell Physiol Biochem; 2018; 49(2):696-705. PubMed ID: 30165366
[TBL] [Abstract][Full Text] [Related]
7. Identification of ESM1 as a Potential Biomarker Involving Drug Sensitivity and the Tumor Immune Microenvironment that Promotes Proliferation of Melanoma.
Wang M; Ge H; Liang S; Chen G
Cell Mol Biol (Noisy-le-grand); 2023 Jun; 69(6):160-167. PubMed ID: 37605575
[TBL] [Abstract][Full Text] [Related]
8. TCP1 regulates PI3K/AKT/mTOR signaling pathway to promote proliferation of ovarian cancer cells.
Weng H; Feng X; Lan Y; Zheng Z
J Ovarian Res; 2021 Jun; 14(1):82. PubMed ID: 34162426
[TBL] [Abstract][Full Text] [Related]
9. Endothelial cell-specific molecule 1 drives cervical cancer progression.
Lu J; Liu Q; Zhu L; Liu Y; Zhu X; Peng S; Chen M; Li P
Cell Death Dis; 2022 Dec; 13(12):1043. PubMed ID: 36522312
[TBL] [Abstract][Full Text] [Related]
10. ESM1 promotes triple-negative breast cancer cell proliferation through activating AKT/NF-κB/Cyclin D1 pathway.
Liu W; Yang Y; He B; Ma F; Sun F; Guo M; Zhang M; Dong Z
Ann Transl Med; 2021 Apr; 9(7):533. PubMed ID: 33987231
[TBL] [Abstract][Full Text] [Related]
11. ESM1 promotes angiogenesis in colorectal cancer by activating PI3K/Akt/mTOR pathway, thus accelerating tumor progression.
Yang L; Dong Z; Li S; Chen T
Aging (Albany NY); 2023 Mar; 15(8):2920-2936. PubMed ID: 37100467
[TBL] [Abstract][Full Text] [Related]
12. NUF2 promotes tumorigenesis by interacting with HNRNPA2B1 via PI3K/AKT/mTOR pathway in ovarian cancer.
Ren M; Zhao H; Gao Y; Chen Q; Zhao X; Yue W
J Ovarian Res; 2023 Jan; 16(1):17. PubMed ID: 36670423
[TBL] [Abstract][Full Text] [Related]
13. TEX19 promotes ovarian carcinoma progression and is a potential target for epitope vaccine immunotherapy.
Xu Z; Tang H; Zhang T; Sun M; Han Q; Xu J; Wei M; Yu Z
Life Sci; 2020 Jan; 241():117171. PubMed ID: 31843525
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive bioinformatics analysis confirms RBMS3 as the central candidate biological target for ovarian cancer.
Wang M; Fu X; Wang W; Zhang Y; Jiang Z; Gu Y; Chu M; Shao Y; Li S
Med Eng Phys; 2022 Dec; 110():103883. PubMed ID: 36075788
[TBL] [Abstract][Full Text] [Related]
15. microRNA-1271-5p/TIAM1 suppresses the progression of ovarian cancer through inactivating Notch signaling pathway.
Han FJ; Li J; Shen Y; Guo Y; Liu YC; Yu Y; Xu JY; Liu SX; Wang YH
J Ovarian Res; 2020 Sep; 13(1):110. PubMed ID: 32948241
[TBL] [Abstract][Full Text] [Related]
16. SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis.
Yang M; Xie X; Ding Y
Oncol Rep; 2016 Mar; 35(3):1796-806. PubMed ID: 26750614
[TBL] [Abstract][Full Text] [Related]
17. F-Box and Leucine-Rich Repeat Protein 20 (FBXL20), Negatively Regulated by microRNA (miR)-195-5p, Accelerates the Malignant Progression of Ovarian Cancer.
Wu D; Liu C; Hong L
Mol Biotechnol; 2021 Dec; 63(12):1235-1243. PubMed ID: 34338995
[TBL] [Abstract][Full Text] [Related]
18. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
[TBL] [Abstract][Full Text] [Related]
19. Targeting ESM1/ VEGFα signaling axis: a promising therapeutic avenue for angiogenesis in cervical squamous cell carcinoma.
Li D; Su X; Xue S; Yao L; Yu D; Tang X; Huang Y
J Cancer; 2023; 14(10):1725-1735. PubMed ID: 37476182
[No Abstract] [Full Text] [Related]
20. UBE2T is upregulated, predicts poor prognosis, and promotes cell proliferation and invasion by promoting epithelial-mesenchymal transition via inhibiting autophagy in an AKT/mTOR dependent manner in ovarian cancer.
Huang W; Huang H; Xiao Y; Wang L; Zhang T; Fang X; Xia X
Cell Cycle; 2022 Apr; 21(8):780-791. PubMed ID: 35130130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
